Who are Liposomal cytarabine-daunorubicin for injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Liposome-encapsulated Daunorubicin-Cytarabine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/liposomal-cytarabine-daunorubicin-for-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Liposomal cytarabine-daunorubicin for injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liposomal cytarabine-daunorubicin for injection (Liposomal cytarabine-daunorubicin for injection) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Liposomal chemotherapy combination. Area: Oncology.

phase 3 Liposomal chemotherapy combination DNA polymerase (cytarabine); Topoisomerase II (daunorubicin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Liposomal cytarabine-daunorubicin for injection (Liposomal cytarabine-daunorubicin for injection) — CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. This liposomal formulation delivers cytarabine and daunorubicin directly into leukemic cells, where both drugs inhibit DNA synthesis and induce apoptosis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Liposomal cytarabine-daunorubicin for injection TARGET	Liposomal cytarabine-daunorubicin for injection	CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	phase 3	Liposomal chemotherapy combination	DNA polymerase (cytarabine); Topoisomerase II (daunorubicin)
Liposome-encapsulated Daunorubicin-Cytarabine	Liposome-encapsulated Daunorubicin-Cytarabine	Fred Hutchinson Cancer Center	phase 3	Liposomal chemotherapy combination	DNA (topoisomerase II for daunorubicin; DNA polymerase for cytarabine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Liposomal chemotherapy combination class)

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 drug in this class
Fred Hutchinson Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Liposomal cytarabine-daunorubicin for injection — Competitive Intelligence Brief. https://druglandscape.com/ci/liposomal-cytarabine-daunorubicin-for-injection. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab